We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $143M
1-Year Est. Return 773.18%
This Fund
S&P 500
This Quarter Est. Return
+81.75%
1 Year Est. Return
+773.18%
3 Year Est. Return
+7,269.42%
5 Year Est. Return
+14,284.66%
10 Year Est. Return
+1,769,765.59%
AUM
$99.4M
AUM Growth
-$24.1M
Cap. Flow
-$19.6M
Cap. Flow %
-19.71%
Top 10 Hldgs %
60.37%
Holding
49
New
8
Increased
12
Reduced
15
Closed
10

Top Buys

Rank Stock Value
1
DRUG
Bright Minds Biosciences
DRUG
+$2.43M
2
TRVI icon
Trevi Therapeutics
TRVI
+$1.54M
3
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$1.35M
4
NAMS icon
NewAmsterdam Pharma
NAMS
+$1.06M
5
ZYME icon
Zymeworks
ZYME
+$940K

Top Sells

Rank Stock Value
1
PCVX icon
Vaxcyte
PCVX
+$8.98M
2
ACLX
Arcellx
ACLX
+$4.44M
3
KURA icon
Kura Oncology
KURA
+$3.85M
4
TSHA icon
Taysha Gene Therapies
TSHA
+$2.56M
5
CMPS
Compass Pathways
CMPS
+$2.43M

Sector Composition

Rank Sector Weight
1 Healthcare 99.98%
2 Miscellaneous 0.02%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OCUL icon
1
Ocular Therapeutix
OCUL
$2.23B
$9.49M 9.55%
1,111,071
-79,000
-7% -$771K
INSM icon
2
Insmed
INSM
$27.1B
$7.24M 7.28%
104,800
-2,700
-3% -$194K
TRML
3
DELISTED
Tourmaline Bio
TRML
$7.14M 7.18%
351,842
+19,747
+6% +$497K
CRNX
4
DELISTED
Crinetics Pharmaceuticals
CRNX
$6.28M 6.32%
122,900
-8,800
-7% -$492K
ELVN icon
5
Enliven Therapeutics
ELVN
$3.68B
$6.02M 6.05%
267,368
-29,000
-10% -$752K
WHWK
6
Whitehawk Therapeutics
WHWK
$233M
$5.83M 5.87%
1,849,402
– –
PRAX icon
7
Praxis Precision Medicines
PRAX
$8.67B
$5.19M 5.23%
67,500
+10,000
+17% +$724K
RVMD icon
8
Revolution Medicines
RVMD
$42.2B
$4.89M 4.92%
111,700
+3,700
+3% +$187K
ARGX icon
9
argenx
ARGX
$62.3B
$4.25M 4.28%
6,910
+1,010
+17% +$592K
PCVX icon
10
Vaxcyte
PCVX
$8.98B
$3.68M 3.71%
45,000
-90,400
-67% -$8.98M
TRVI icon
11
Trevi Therapeutics
TRVI
$2.17B
$3.18M 3.2%
771,958
+481,458
+166% +$1.54M
ASND icon
12
Ascendis Pharma A/S
ASND
$15.7B
$3.16M 3.18%
22,976
+1,976
+9% +$260K
MREO
13
Mereo BioPharma
MREO
$46.3M
$2.73M 2.74%
779,308
-481,392
-38% -$1.89M
DRUG
14
Bright Minds Biosciences
DRUG
$604M
$2.49M 2.5%
+69,124
New +$2.43M
TERN
15
DELISTED
Terns Pharmaceuticals
TERN
$2.48M 2.49%
447,500
-39,500
-8% -$267K
EWTX icon
16
Edgewise Therapeutics
EWTX
$5.1B
$2.34M 2.35%
87,658
+24,658
+39% +$785K
BBOT
17
BridgeBio Oncology
BBOT
$392M
$1.9M 1.91%
180,945
– –
UNCY icon
18
Unicycive Therapeutics
UNCY
$133M
$1.83M 1.84%
230,300
+32,380
+16% +$179K
RCKT icon
19
Rocket Pharmaceuticals
RCKT
$384M
$1.69M 1.7%
134,500
-55,500
-29% -$835K
LQDA icon
20
Liquidia Corp
LQDA
$6.12B
$1.62M 1.63%
137,709
+64,209
+87% +$702K
MRSN
21
DELISTED
Mersana Therapeutics
MRSN
$1.6M 1.61%
44,820
-3,180
-7% -$165K
TSHA icon
22
Taysha Gene Therapies
TSHA
$1.68B
$1.53M 1.54%
884,244
-1,234,748
-58% -$2.56M
TECX
23
Tectonic Therapeutic
TECX
$532M
$1.52M 1.53%
33,008
+19,308
+141% +$817K
CDTX
24
DELISTED
Cidara Therapeutics
CDTX
$1.46M 1.47%
+54,473
New +$885K
NAMS icon
25
NewAmsterdam Pharma
NAMS
$2.62B
$1.28M 1.29%
+50,000
New +$1.06M
1
2

Similar funds

FPC
Flax Pond Capital Falmouth, Massachusetts $143M AUM
WWM
Woodside Wealth Management Framingham, Massachusetts $144M AUM 22.2% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
BOM
Bank of Marin Novato, California $143M AUM 26.89% 1-Year Est. Return
PWM
Pathway Wealth Management Dallas, Texas $143M AUM
FF
Fox Financial Wyomissing, Pennsylvania $144M AUM 28.05% 1-Year Est. Return
JPT
Jordan Park Trust Portsmouth, New Hampshire $143M AUM 15.59% 1-Year Est. Return
BJF
Blue Jean Financial Albany, New York $144M AUM

Acuta Capital Partners's Q4 2024 Portfolio in Review

As of Q4 2024, Acuta Capital Partners held 49 positions worth $99.4M, down 19% from $123M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Acuta Capital Partners withdrew a net $19.6M in Q4 2024, closing 10 positions and reducing 15 holdings. Its most notable exit was Kura Oncology, an estimated $3.85M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Acuta Capital Partners opened a new position in Bright Minds Biosciences worth $2.49M.

  • Acuta Capital Partners's largest Q4 2024 buy was Bright Minds Biosciences: 69,124 shares worth $2.49M.
  • Acuta Capital Partners added most to Trevi Therapeutics in Q4 2024, an estimated $1.54M increase.
  • Acuta Capital Partners's biggest Q4 2024 reduction was Vaxcyte, cutting an estimated $8.98M.
  • Acuta Capital Partners fully exited Kura Oncology in Q4 2024, selling an estimated $3.85M.
  • Acuta Capital Partners's ten largest holdings make up 60% of its $99.4M portfolio in Q4 2024.
  • Acuta Capital Partners opened 8 new positions and closed 10 in Q4 2024.
  • Acuta Capital Partners's portfolio value fell 19% quarter-over-quarter to $99.4M.

Based on Acuta Capital Partners's 13F filing for Q4 2024, filed 14 Feb 2025.